Shannon Setzer, MD | |
1600 Ellis Street, Suite 3b, Bozeman, MT 59715 | |
(406) 587-7546 | |
(406) 585-5672 |
Full Name | Shannon Setzer |
---|---|
Gender | Female |
Speciality | Dermatology |
Experience | 24 Years |
Location | 1600 Ellis Street, Bozeman, Montana |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1639355928 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | 11661 (Montana) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Shannon Setzer Md Pc | 5698822989 | 4 |
News Archive
Medica today became the first health plan to launch a mobile application to help consumers compare cost information for a variety of medical procedures. The app, based on the Web site MainStreetMedica.com, is available at the iPhone App Store.
The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A's pro-inflammatory activity, according to a study by National Eye Institute researchers.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Watson Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.
› Verified 7 days ago
Entity Name | Shannon Setzer Md Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1316188337 PECOS PAC ID: 5698822989 Enrollment ID: O20090401000475 |
News Archive
Medica today became the first health plan to launch a mobile application to help consumers compare cost information for a variety of medical procedures. The app, based on the Web site MainStreetMedica.com, is available at the iPhone App Store.
The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A's pro-inflammatory activity, according to a study by National Eye Institute researchers.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Watson Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Shannon Setzer, MD 1600 Ellis Street, Suite 3b, Bozeman, MT 59715 Ph: (406) 587-7546 | Shannon Setzer, MD 1600 Ellis Street, Suite 3b, Bozeman, MT 59715 Ph: (406) 587-7546 |
News Archive
Medica today became the first health plan to launch a mobile application to help consumers compare cost information for a variety of medical procedures. The app, based on the Web site MainStreetMedica.com, is available at the iPhone App Store.
The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A's pro-inflammatory activity, according to a study by National Eye Institute researchers.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
Watson Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.
› Verified 7 days ago
Dr. Alyson Anne Thede, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 815 N 5th Ave Unit 202, Bozeman, MT 59715 Phone: 406-545-2555 Fax: 406-545-2554 | |
Teresa P Mann, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2233 W Kagy Blvd Ste 2, Bozeman, MT 59718 Phone: 406-586-7873 Fax: 406-586-2332 | |
Phoebe Koch, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1905 W College St, Bozeman, MT 59718 Phone: 406-587-4432 Fax: 406-587-7015 | |
Dr. Jeffrey M Williams, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 815 N 5th Ave Unit 202, Bozeman, MT 59715 Phone: 406-545-2555 | |
Dr. Michael Colin Milliken, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1905 W College St, Bozeman, MT 59718 Phone: 406-587-4432 Fax: 406-587-7015 | |
Suzanne B Schoelch, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1727 W College St, Bozeman, MT 59715 Phone: 406-587-4432 Fax: 406-587-7015 |